Sansei Guojian: The application for the commercialization of the new drug, a recombined humanized monoclonal antibody injection targeting IL-4R, has been accepted.

San Sheng Guo Jian Announcement: Recently, the new drug application for the company's product, a recombined humanized monoclonal antibody injection targeting IL-4R, has been accepted. SSGJ-611 is a monoclonal antibody against IL-4R that the company independently designed, screened, and humanized, with a completely new amino acid sequence. SSGJ-611 is able to block the signaling of IL-4 and IL-13 by specifically binding to IL-4R, thereby relieving diseases such as atopic dermatitis.